Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001248419 | SCV001421906 | pathogenic | Carnitine palmitoyltransferase II deficiency | 2024-12-10 | criteria provided, single submitter | clinical testing | This sequence change replaces histidine, which is basic and polar, with glutamine, which is neutral and polar, at codon 555 of the CPT2 protein (p.His555Gln). This variant is present in population databases (no rsID available, gnomAD 0.003%). This missense change has been observed in individual(s) with features of autosomal recessive carnitine palmitoyltransferase II deficiency (PMID: 29744303; internal data). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 972398). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt CPT2 protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. |
Natera, |
RCV001248419 | SCV002092674 | uncertain significance | Carnitine palmitoyltransferase II deficiency | 2021-04-27 | no assertion criteria provided | clinical testing |